Skip to content

Dr. Reddy’s rolls out aspirin and extended-release dipyridamole capsules

Dr. Reddy’s Laboratories Ltd. recently announced the launch of aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules in the United States market from the U.S. Food and Drug Administration.

Table of Contents

PRINCETON, N.J. — Dr. Reddy’s Laboratories Ltd. recently announced the launch of aspirin and extended-release dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules in the United States market from the U.S. Food and Drug Administration.

The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy’s Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.

Comments

Latest